Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06313853
Other study ID # STUDY00007068
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 22, 2024
Est. completion date October 2027

Study information

Verified date May 2024
Source University of Rochester
Contact Allison Magnuson
Phone 585-602-5085
Email allison_magnuson@urmc.rochester.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Building upon prior work, the investigator team developed a communication intervention for older adults with ADRD who are considering a decision about cancer management (adapted intervention: COACH-Cog). The investigators hypothesize that for patients with dual diagnoses of ADRD and cancer, COACH-Cog will increase autonomy support of care partners and patients in the decision-making process, leading to greater acknowledgement and support of cognitive concerns and cognitive-related goals, thereby improving goal concordant care. The investigators are conducting a pilot randomized controlled trial (RCT; cluster randomized by physician) including approximately 45 oncology clinicians and 130 patient/care partner dyads evaluating the effect of COACH-Cog on care partner and patient autonomy support, care partner well-being, goal-concordance, and communication.


Recruitment information / eligibility

Status Recruiting
Enrollment 305
Est. completion date October 2027
Est. primary completion date April 2027
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility PATIENTS: Patient Inclusion Criteria: 1. Be age 65 or older 2. Have a clinical diagnosis of Alzheimer's disease or related dementia (ADRD [Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, or dementia of unknown subtype]) 3. Have a clinical diagnosis of cancer (any type or stage) 4. Anticipate a potential decision about cancer-related management, as confirmed by the patient's primary medical oncology clinician. 5. Have a care partner willing and able to participate in the study 6. Are able to read and understand English. The communication coaching session will be delivered in English, thus necessitating this requirement. 7. Be able to provide informed consent (as measured by UBACC) or have a Legally Authorized Representative to provide informed consent Patient Exclusion Criteria: Patient exclusion criteria: None CARE PARTNER: Care partner inclusion criteria: 1. Age 18 or over 2. Able to read and understand spoken English 3. Able to provide informed consent Care partner exclusion criteria: None ONCOLOGY CLINICIAN: Oncology clinician inclusion criteria: 1. Oncology clinicians affiliated with the Wilmot Cancer Institute 2. Do not intend to move or retire within the next 2 years. Oncology clinician exclusion criteria: None

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
COACH-Cog
Oncology clinician intervention components: 1) a brief training video (completed once during the duration of the study following enrollment and randomization), 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments Patient/Care partner dyad intervention components: 1) Care partners (and patients if able) will participate in a one-time communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.

Locations

Country Name City State
United States University of Rochester Wilmot Cancer Institute Rochester New York

Sponsors (2)

Lead Sponsor Collaborator
University of Rochester National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Patient: Patient-Centered Communication in Cancer Care (PCC-Ca) Patient communication; score range 1-5; higher scores are better 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter
Other Patient: Health Care Climate Questionnaire (HCCQ) Patient autonomy support; score range: 6-42; higher score is better. 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter
Other Patient: Health Care Climate Questionnaire - Age (HCCQ-Age) Patient Age-related autonomy support; score range 0-28; higher scores are worse 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter
Other Patient Decision Regret Scale Patient: Decision regret; score range 5-25; higher score is worse 3-months post-oncology clinical encounter
Other Physician Decision Regret Scale Physician: Decision regret; score range 5-25; higher score is worse 3-months post-oncology clinical encounter
Primary Care Partner: Health Care Climate Questionnaire (HCCQ) Care Partner autonomy support; score range: 6-42; higher score is better. 4-weeks post oncology clinical encounter
Secondary Montgomery Borgatta Caregiving Burden Scale Care partner well-being: Caregiver burden; total score range 14-70; range for subscales 4-30; higher score is better for Objective Subscale; Higher score is worse for Subjective Stress and Subjective Demand subscales 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter
Secondary World Health Organization Quality of Life Brief Version (WHOQOL-BREF) Care partner well-being: Quality of Life; Total score range 26-130; domain range 3-40; higher score is better 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter
Secondary Care Partner PROMIS Depression Care partner well-being: Depression; score range 4-20; higher score is worse 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter
Secondary Care partner PROMIS Anxiety Care partner well-being: Anxiety; score range 4-20; higher score is worse 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter
Secondary Care partner: Patient-Centered Communication in Cancer Care (PCC-Ca) Care partner communication; score range 1-5; higher scores are better 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter
Secondary Care partner: Health Care Climate Questionnaire - Age (HCCQ-Age) Care partner Age-related autonomy support; score range 0-28; higher scores are worse 4-weeks post-oncology clinical encounter and 3-months post-oncology clinical encounter
Secondary Care partner: Qualitative assessment of goal concordance Care partner: Goal concordance; qualitative analysis if goal concordance occurred (yes/no); range 0-130; higher number better 3-months post-oncology clinical encounter
Secondary Care partner: Decision Regret Scale Care partner: Decision regret; score range 5-25; higher score is worse 3-months post-oncology clinical encounter
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients